Eli Lil­ly wraps up fifth and fi­nal tirzepatide PhI­II tri­al, claim­ing a win over Sanofi's Lan­tus. The FDA awaits

4 years ago
R&D

Aim­ing to spur the im­mune re­spons­es that check­point in­hibitors can't, Swiss biotech Num­ab earns fresh round of cash

4 years ago
Financing

#AS­CO21: Ab­b­Vie-part­nered Chi­nese biotech with first-in-class am­bi­tions show­cas­es ear­ly da­ta on CD73 an­ti­body

4 years ago
R&D

Voy­ager CEO An­dre Turenne re­signs amid set­backs, as the biotech piv­ots back to dis­cov­ery

4 years ago
People

#AS­CO21: Take­da flesh­es out case for oral EGFR drug with fol­low-up piv­otal da­ta in non-small cell lung can­cer

4 years ago
R&D

#AS­CO21: With Bris­tol My­ers set for its own big LAG-3 up­date at AS­CO, Mer­ck touts ear­ly suc­cess for a po­ten­tial ...

4 years ago
R&D

#AS­CO21: EQRx's cheap­er EGFR drug busts Ires­sa in head-to-head test, and a US fil­ing could be right down the road

4 years ago
R&D

#AS­CO21: Mer­ck tacks on ar­mor in ear­ly-line can­cer fight with 2 Keytru­da wins set­ting the tone

4 years ago
R&D

#AS­CO21: Adap­ti­m­mune gives first glimpse at piv­otal da­ta for what they hope will be first ap­proved TCR

4 years ago
R&D

#AS­CO21: Al­lo­gene sets out to prove that their off-the-shelf ap­proach to CAR-T can beat the per­son­al­ized ap­proach

4 years ago
R&D

#AS­CO21: Ahead of Au­gust PDU­FA date, Astel­las and Seagen sweet­en Pad­cev pitch with new da­ta

4 years ago
R&D

#AS­CO21: J&J busts out a small up­date for its an­ti­body-TKI com­bo in lung can­cer — whet­ting ap­petites as FDA thinks ...

4 years ago
R&D

Hours af­ter an­oth­er FDA de­lay, Io­vance CEO re­signs — shares plum­met

4 years ago
Cell/Gene Tx

FDA+ roundup: Flur­ry of guid­ance doc­u­ments, up­dat­ed risk cri­te­ria for Covid-19 mAbs, per­son­nel moves and more

4 years ago
FDA+

Opin­ion: Con­gress needs to take a hard look at what went on at Trump's White House dur­ing the pan­dem­ic

4 years ago
FDA+
Opinion

Idera of­fi­cial­ly puts to rest its Phase III tri­al in ad­vanced melanoma; BeiGene nabs pri­or­i­ty re­view for sN­DA

4 years ago
News Briefing

Pas­sage Bio los­es two ex­ecs in one week as CFO, CMO pack their bags amid 'chang­ing need­s'

4 years ago
People

Look­ing to re­shape the metasta­t­ic can­cer land­scape, Hi­ber­Cell fills the tank with a slate of mid-stage tests queued ...

4 years ago
Financing

Ac­celeron un­corks more mid-stage da­ta for PAH drug so­tater­cept as part of the drug's res­ur­rec­tion cam­paign

4 years ago
R&D

Covid-19 roundup: Study sug­gests As­traZeneca/Ox­ford boost­er is ef­fec­tive against vari­ants — re­port; IF­P­MA is­sues ...

4 years ago
Coronavirus

Ther­mo Fish­er part­ners with UCSF to pro­vide a one-stop shop for ear­ly biotech man­u­fac­tur­ing

4 years ago
Manufacturing

Bris­tol My­ers ex­pands Cel­gene-era deal with Ex­sci­en­tia, tak­ing its AI R&D en­gine to the next step

4 years ago
Deals
AI

Lega­cies: 60 bio­phar­ma pi­o­neers over 60 who helped birth a tech rev­o­lu­tion in the mak­ing

4 years ago
People
Special

CMC holdup de­lays Io­vance fil­ing again — to 2022 — as FDA seeks more as­say da­ta for TIL ther­a­py

4 years ago
Cell/Gene Tx
FDA+
First page Previous page 691692693694695696697 Next page Last page
A service from the Financial Times